Home LiteratureArticle Details
PMID: 10495128 Published · ppublish English Comparative Study Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells.

Bone ·Vol. 25 ·No. 3 ·1999-09-00 ·Pages 255-9

Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S

Abstract

Recent studies have identified osteoprotegerin ligand (OPG-L) as the essential factor required for osteoclastogenesis, and that the effects are prevented by its soluble receptor, osteoprotegerin (OPG). However, there are limited data at present on the regulation of OPG-L expression in human osteoblastic cells by other cytokines. Because interleukin (IL)-1beta, tumor necrosis factor (TNF)-alpha, and IL-6 all increase osteoclastogenesis, we assessed whether OPG-L mRNA steady-state levels were regulated by these cytokines in human osteoblastic cells. By northern analysis, IL-1beta (5 nmol/L) and TNF-alpha (9 nmol/L) increased OPG-L mRNA steady-state levels by up to two- to three-fold in normal marrow stromal cells (MS), an immortalized marrow stromal cell line (hMS), and the osteosarcoma cell line, MG-63, whereas IL-6 (2 nmol/L, with or without its soluble receptor) had no effect on OPG-L mRNA levels in any of these cells. IL-1beta and TNF-alpha increased OPG-L mRNA steady-state levels in the normal MS cells and the hMS cell line in a time- and dose-dependent fashion by up to 4.1-fold and up to 2.6-fold, respectively. Our data are thus consistent with the hypothesis that the proinflammatory and bone-resorbing cytokines, IL-1beta and TNF-alpha, but not IL-6, may stimulate osteoclastogenesis by inducing the expression of OPG-L.

MeSH Terms
Blotting, Northern Bone Marrow Cells/cytology,drug effects,metabolism Carrier Proteins/biosynthesis,genetics Cell Line, Transformed Dose-Response Relationship, Drug Gene Expression Regulation/drug effects Humans Interleukin-1/genetics,pharmacology Interleukin-6/genetics,pharmacology Ligands Membrane Glycoproteins/biosynthesis,genetics Osteoblasts/drug effects,metabolism RANK Ligand RNA, Messenger/metabolism Receptor Activator of Nuclear Factor-kappa B Tumor Cells, Cultured Tumor Necrosis Factor-alpha/genetics,pharmacology
Chemicals
Carrier Proteins Interleukin-1 Interleukin-6 Ligands Membrane Glycoproteins RANK Ligand RNA, Messenger Receptor Activator of Nuclear Factor-kappa B TNFRSF11A protein, human TNFSF11 protein, human Tumor Necrosis Factor-alpha
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Hofbauer L C
Endocrine Research Unit, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA.
Lacey D L
Dunstan C R
Spelsberg T C
Riggs B L
Khosla S
Article Info
Journal
Bone
Abbr.
Bone
ISSN
8756-3282
Published
1999-09-00
Pages
255-9
Language
English
Region
United States
NLM ID
8504048
Subset
IM
Grants
NIA NIH HHS · AG-04875 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com